OCCIDENTAL CHEMICAL CORPORATION v. 21ST CENTURY FOX AMERICA, INC.

District Court, D. New Jersey·Decided June 13, 2022·No. 2:18-cv-11273·Unknown

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY Civil Action No. 18-11273 (MCA)(LDW) OCCIDENTAL CHEMICAL CORPORATION, SPECIAL MASTER DECISION GRANTING IN PART AND DENYING Plaintiff, IN PART SMALL PARTIES GROUP DEFENDANTS’ MOTION FOR A v. DETERMINATION OF PLAINTIFF’S RESPONSES TO REQUESTS FOR 21ST CENTURY FOX AMERICA, INC., et ADMISSION AND DENYING al., PLAINTIFF’S CROSS-MOTION FOR A PROTECTIVE ORDER Defendants. INTRODUCTION This matter comes by way of a Motion, filed by the Small Parties Group Defendants (“SPG Defendants”) on January 14, 2022, pursuant to Federal Rule of Civil Procedure 36(a)(6), for a determination regarding Plaintiff, Occidental Chemical Corporation’s (“OxyChem’s”), amended answers to SPG Defendants’ Requests for Admission (the “RFAs”) (ECF No. 1945) (the “RFA Motion”). SPG Defendants contend that OxyChem’s amended responses are insufficient and, thus, seek an Order deeming the amended responses to the RFAs admitted. On February 24, 2022, OxyChem filed opposition to the RFA Motion and, pursuant to Federal Rule of Civil Procedure 26(c) and L.Civ.R. 7.1(h), a cross-motion for a protective order (ECF No. 1997) (“Cross-Motion”). OxyChem asserts that the RFAs violate the purpose of Federal Rule of Civil Procedure 36 because the RFAs are oppressive and unduly burdensome. On March 28, 2022, SPG Defendants’ filed a reply in further support of the RFA Motion and in opposition to the Cross-Motion (ECF No. 2011) (the “Reply”). The parties have participated in several meet-and-confers to resolve the discovery dispute over the RFAs, but were unable to come to a full resolution. However, the parties have agreed that the dispute is limited to 267 RFAs identified in Exhibit A to OxyChem’s November 19, 2021, letter to SPG Defendants (ECF No. 1907) (the “Nov. 19 Letter”). The motions, therefore, are ripe for a decision by the Special Master. For the reasons set forth herein, the RFA Motion is granted in part and denied in part, and the Cross-Motion is denied. The Special Master’s Findings as to all disputed RFAs are detailed in Exhibit A to this Decision and OxyChem has 30 days to provide

amended answers as required in Exhibit A. BACKGROUND

A. SPG Defendants’ RFAs

On July 13, 2021, SPG Defendants served 449 RFAs on OxyChem (ECF No. 1504) (the “July 13 Letter”). See July 13 Letter at 1; see also Exhibit A to the RFA Motion.1 On August 13, 2021, OxyChem sent a letter to SPG Defendants to request a meet-and- confer to discuss the RFAs. See ECF No. 1945-9. On August 23, 2021, OxyChem sent a letter to SPG Defendants wherein OxyChem: (i) objected to the RFAs as unduly burdensome; (ii) proposed a meet-and-confer to discuss the RFAs; and (iii) requested that the Special Master grant leave to file a motion to quash or for protection. See July 13 Letter. On September 2, 2021, the parties held a meet-and-confer on the RFAs. See ECF No. 1997-4. On September 10, 2021, OxyChem provided its initial responses to the RFAs. See ECF No. 1945-3 at 4. On October 13, 2021, SPG Defendants sent a letter to OxyChem stating that OxyChem’s initial responses to the RFAs were improper and included inappropriate answers and/or denials.

1 SPG Defendants served the RFAs prior to the parties’ agreement that the universe of RFAs is limited to 267 RFAs. See ECF No. 1945-10 (“Oct. 13 Letter”). SPG Defendants also requested a meet-and-confer to discuss the responses. OxyChem did not respond to the Oct. 13 Letter. On October 27, 2021, SPG Defendants sent a follow up letter to OxyChem. See ECF No. 1945-11. On November 10, 2021, the parties held a second meet-and-confer to discuss OxyChem’s

initial responses to the RFAs. See ECF No. 1945-2. On November 17, 2021, the Special Master held a status conference (the “November Status Conference”). At the November Status Conference, OxyChem reported that it agreed to provide amended responses to the RFAs on or about December 8, 2021. Prior to doing so, however, OxyChem requested that SPG Defendants submit correspondence detailing which, if any, of the 449 RFAs SPG Defendants planned to withdraw. On November 19, 2021, OxyChem filed the Nov. 19 Letter wherein OxyChem requested confirmation that the discovery dispute was limited to the 267 RFAs listed in Exhibit A to the Nov. 19 Letter.

On November 30, 2021, SPG Defendants confirmed that the dispute was limited to the 267 RFAs identified in Exhibit A, and that any motion practice related to the RFAs would not include RFAs outside the 267. See ECF No. 1910. On December 8, 2021, OxyChem served amended answers and objections to the RFAs (the “Amended Responses”). See ECF No. 1945-12. On December 9, 2021, OxyChem filed a letter to the Special Master to provide an update on the dispute. See ECF No. 1922 at 1. On December 15, 2021, SPG Defendants filed a letter stating that SPG Defendants planned to file a motion to determine the sufficiency of the Amended Responses. See ECF No. 1929. B. SPG Defendants’ RFA Motion

On January 14, 2022, SPG Defendants filed the RFA Motion. SPG Defendants contend that the Amended Responses should be deemed admitted, or alternatively, OxyChem should be directed to serve additional amended responses for failing to properly admit or deny the RFAs. To that end, SPG Defendants set forth three arguments in support of the RFA Motion: (i) OxyChem relied on boilerplate objections; (ii) OxyChem provided evasive answers to straightforward requests; and (iii) OxyChem offers irrelevant, self-serving explanations. SPG Defendants also rely on unpublished cases from the Eastern District of Pennsylvania for the proposition that responses, which do not go to the truth contained in the RFAs and purportedly frustrate the purpose of Federal Rule of Civil Procedure 36, require that the responding party submit amended responses. See United States v. Lorenzo, 1990 U.S. Dist. LEXIS 7362 (E.D. Pa. June 14, 1990); Penn Eng’g & Mfg. Corp. v. Peninsula Components, Inc., 2021 U.S. Dist. LEXIS 64382 (E.D. Pa. April 1, 2021). C. OxyChem’s Cross-Motion for a Protective Order

On February 24, 2022, OxyChem filed the Cross-Motion. By way of support, OxyChem asserts that a protective order should be entered because: (i) the RFAs are oppressive and unduly burdensome by sheer number, form, and subject; (ii) the Amended Responses are not evasive; and (iii) OxyChem provided qualifications and explanations where necessary. In citing to a decision from the District for the District of Columbia, Harris v. Koenig, 271 F.R.D. 356, 372 (D.D.C. 2010), OxyChem asserts that the propounding parties’ disagreement with an answer is neither a proper basis for finding a response insufficient, nor grounds for deeming requests admitted. OxyChem also cites to an unpublished decision from this District for the proposition that whether OxyChem properly denied an RFA requires an analysis of the denial and qualification, if any. In re Valeant Pharms. Int’l Secs. Litig., 2021 U.S. Dist. LEXIS 108161, *50 (D.N.J. April 1, 2021) (citations omitted). Finally, OxyChem asserts that should the Special Master find any of the Amended Responses insufficient, the proper relief is to order OxyChem to submit additional amended responses.

D. SPG Defendants’ Reply

Free access — add to your briefcase to read the full text and ask questions with AI

OCCIDENTAL CHEMICAL CORPORATION v. 21ST CENTURY FOX AMERICA, INC., (D.N.J. 2022).

OCCIDENTAL CHEMICAL CORPORATION v. 21ST CENTURY FOX AMERICA, INC. (OCCIDENTAL CHEMICAL CORPORATION v. 21ST CENTURY FOX AMERICA, INC.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related